Annexon, Inc. (ANNX)
| Market Cap | 942.21M +306.4% |
| Revenue (ttm) | n/a |
| Net Income | -202.67M |
| EPS | -1.13 |
| Shares Out | 189.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,618,492 |
| Open | 5.180 |
| Previous Close | 5.250 |
| Day's Range | 4.945 - 5.210 |
| 52-Week Range | 2.030 - 7.180 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 14.71 (+195.98%) |
| Earnings Date | Aug 12, 2026 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ANNX stock is "Buy." The 12-month stock price target is $14.71, which is an increase of 195.98% from the latest price.
News
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon participates in a conference call with JPMorgan
Conference call with management will be held on August 17 at 12 pm hosted by JPMorgan.Webcast Link
Annexon reports Q2 EPS (28c), consensus (24c)
Cash, cash equivalents and short-term investments were $209.2M as of June 30, 2026. Annexon’s (ANNX) current cash, cash equivalents and short-term investments and funds from the credit facility are ex...
Annexon expands Phase 3 ARCHER II trial
Annexon (ANNX) announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of…
Annexon upgraded to Market Perform from Underperform at Citizens
Citizens analyst Jonathan Wolleben upgraded Annexon (ANNX) to Market Perform from Underperform without a price target The firm says adding vision preservation at month 24 as an independent, dual prima...
Annexon Earnings Call Transcript: Q2 2026
Expanded phase III trial for GA with a new 24-month endpoint and reported rapid, positive results for GBS therapy. Financial position strengthened with a $200M credit facility, and key regulatory filings are on track for both programs.
Annexon Earnings release: Q2 2026
Annexon released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Annexon Quarterly report: Q2 2026
Annexon has published its Q2 2026 quarterly earnings report on August 12, 2026.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submissio...
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinfla...
Annexon announces tanruprubart data from FORWARD study
Annexon (ANNX) announced early improvement in strength and clinically meaningful reduction in disability shown with tanruprubart in the first ten U.S. and European patients with Guillain-Barre syndrom...
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
Annexon initiated with an Underperform at Citizens
Citizens initiated coverage of Annexon (ANNX) with an Underperform rating and $3 price target The company is developing first-in-class C1q inhibitors targeting the initiating step of the classical com...
Annexon price target raised to $25 from $11 at Needham
Needham analyst Joseph Stringer raised the firm’s price target on Annexon (ANNX) to $25 from $11 and keeps a Buy rating on the shares. The company plans to announce topline…
Annexon to present vonaprument data at ASRS
Annexon (ANNX) announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists, or ASRS, 44th Annual Scientific Meeting being held July 15-18 ...
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Nedham biotech analysts hold an analyst/industry conference call
Analysts discuss Annexon (ANNX) Vonaprument in geographic atrophy on an Analyst/Industry conference call on July 9 at 9 am.
Annexon Transcript: AGM 2026
The meeting covered progress on late-stage therapies for neuroinflammatory diseases, approved all four shareholder proposals, and confirmed a strong cash position through 2027. Key milestones include regulatory submissions and pivotal data readouts.
Annexon Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pivotal phase III data for vonaprument in geographic atrophy is expected in Q4 2026, focusing on vision preservation as a key differentiator. The company is also advancing tanruprubart for Guillain-Barré syndrome and ANX1502, with a strong cash position supporting execution of major milestones.
Annexon Transcript: Jefferies Global Healthcare Conference 2026
Upcoming catalysts include late-stage data for GBS, GA, and ANX1502, with all programs showing strong differentiation and commercial potential. GA phase III aims to confirm vision preservation, while GBS targets a large, underserved market. Key data readouts are expected in 2024.
Annexon to Participate in Upcoming June Investor Conferences
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato...
Annexon Transcript: Bank of America Global Healthcare Conference 2026
The company highlighted differentiated complement pathway therapies for neuroinflammatory diseases, with late-stage programs in geographic atrophy and Guillain-Barré syndrome showing strong efficacy and safety. Commercial and regulatory strategies are advancing in both the U.S. and Europe, with additional pipeline progress in small molecule candidates.
Annexon initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Annexon (ANNX) with a Neutral rating and $7 price target Annexon is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory diseases vi...
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and n...